Do you want to read an article? Please log in or register.
Protocol and Rationale for the International Lung Screening Trial (ILST)
Lung Cancer
RECOMMENDED
Related content
RECOMMENDED
Lung Cancer
Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial
Chest.
Whittaker Brown SA, Padilla M, Mhango G, Powell C, Salvatore M, Henschke C, Yankelevitz D, Sigel K, de-Torres JP, Wisnivesky J
doi: 10.1016/j.chest.
RECOMMENDED
Lung Cancer
Patient-level trajectories and outcomes after low-dose CT screening in the National Lung Screening Trial
Chest.
Iaccarino JM, Silvestri GA, Wiener RS
doi: 10.1016/j.chest.2019.06.016.
RECOMMENDED
Lung Cancer
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
N Engl J Med.
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, Lammers JJ, Weenink C, Yousaf-Khan U, Horeweg N, van 't Westeinde S, Prokop M, Mali WP, Mohamed Hoesein FAA, van Ooijen PMA, Aerts JGJV, den Bakker MA, Thunnissen E, Verschakelen J, Vliegenthart R, Walter JE, Ten Haaf K, Groen HJM, Oudkerk M, HypoEXIT Study Group
doi: 10.1056/NEJMoa1911793.
RECOMMENDED
Further Publications
Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Labaki WW, Xia M, Murray S, Hatt CR, Al-Abcha A, Ferrera MC, Meldrum CA, Keith LA, Galbán CJ, Arenberg DA, Curtis JL, Martinez FJ, Kazerooni EA, Han MK
doi: 10.1016/j.chest.2020.12.004
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
RECOMMENDED
Lung Cancer
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
Lancet Respir Med.
Altorki NK, Wang X, Wigle , Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman L
doi: 10.1016/S2213-2600
RECOMMENDED
Interstitial Lung Disease
Prospective evaluation of hydroxychloroquine in pediatric interstitial lung diseases: Study protocol for an investigator-initiated, randomized controlled, parallel-group clinical trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1186/s13063-020-4188-4.
RECOMMENDED
Lung Cancer
Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study
Thorax.
Walter JE, Heuvelmans MA, Ten Haaf K, Vliegenthart R, van der Aalst CM, Yousaf-Khan U, van Ooijen PMA, Nackaerts K, Groen HJM, De Bock GH, de Koning HJ, Oudkerk M
doi: 10.1136/thoraxjnl-2018-212152.
RECOMMENDED
Lung Cancer
Analysis of lung cancer risk model (PLCOM2012 and LLPv2) performance in a community-based lung cancer screening programme
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Thorax.
Lebrett MB, Balata H, Evison M, Colligan D, Duerden R, Elton P, Greaves M, Howells J, Irion K, Karunaratne D, Lyons J, Mellor S, Myerscough A, Newton T, Sharman A, Smith E, Taylor B, Taylor S, Walsham A, Whittaker J, Barber PV, Tonge J, Robbins HA, Booton R, Crosbie PAJ
doi: 10.1136/thoraxjnl-2020-214626.